中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Recent advances of quantitative detection methods for HBV cccDNA

DOI: 10.3969/j.issn.1001-5256.2019.06.006
  • Received Date: 2019-05-09
  • Published Date: 2019-06-20
  • Elimination of HBV cccDNA from hepatocytes infected with chronic HBV virus is considered to be the key to eradicating HBV.Monitoring HBV cccDNA before, during, and after viral treatment is essential for routine treatment of patients with chronic hepatitis B. With the introduction of new anti-HBV treatment technologies and new drugs targeting HBV cccDNA, Accurate and sensitive HBV cccDNA assays are urgently needed to evaluate efficacy. In recent years, HBV cccDNA detection methods have achieved gratifying results in both traditional PCR methods and digital PCR methods popular in recent years. In this paper, the advances in HBV cccDNA quantitative detection by qPCR, Magnetic bead capture hybridization, rolling circle amplification combined with in situ PCR, digital PCR and digital PCR assay in single cells were reviewed.

     

  • [1]RAZAVI-SHEARER D, GAMKRELIDZE I, NGUYEN MH, et al.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:A modelling study[J].Lancet Gastroenterol Hepatol, 2018, 3 (6) :383-403.
    [2]CHEN J, WU M, LIU K, et al.New insights into hepatitis B virus biology and implications for novel antiviral strategies[J].Nat Sci Rev, 2015, 2 (4) :296-313.
    [3]SEEGER C, MASON WS.Molecular biology of hepatitis B virus infection[J].Virology, 2015, 8 (12) :672-686.
    [4]LI XL, ZHAO JH, YUAN Q, et al.Detection of HBV covalently closed circular DNA[J].Viruses, 2017, 9 (3) :139-158.
    [5]CAI DW, NIE H, YAN R, et al.A Southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures[J].Methods Mol Biol, 2013, 1030:151-161.
    [6]KOCK J, SCHLICHT HG.Analysis of the earliest steps of hepadnavirus replication:Genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity[J].J Virol, 1993, 67 (11) :4867-4874.
    [7]ADDISON WR, WONG WW, FISCHER KP, et al.A quantitative competitive PCR assay for the covalently closed circular form of the duck hepatitis B virus[J].Antiviral Res, 2000, 48 (7) :27-37.
    [8]HE ML, WU J, CHEN Y, et al.A new and sensitive method for the quantification of HBV cccDNA by real-time PCR[J].Biochem Biophys Res Commun, 2002, 295:1102-1107.
    [9]SHAO JB, CHEN Z, NI WQ, et al.A quantitative method to detect HBV cccDNA by chimeric primer and real-time polymerase chain reaction[J].J Virol Method, 2003, 112:45-52.
    [10]WONG DK, YUEN MF, YUAN H, et al.Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients[J].Hepatology, 2004, 40 (3) :727-737.
    [11]WERLE-LAPOSTOLLE B, BOWDEN S, ZOULIM F, et al.Persistence of HBV cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroenterology, 2004, 126 (11) :1750-1758.
    [12]NASSAL M.HBV cccDNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J].Gut, 2015, 34 (1) :1-13.
    [13]LUO J, CUI X, HU J.Identification of intermediate in hepatitis B virus cccDNA.formation and sensitive and selective cccD-NA detection[J].J Virol, 2017, 8 (3) :539-556.
    [14]JIANG PX, MAO RC, ZHANG JM, et al.Exonuclease I and IIIimprove the detection efficacy of hepatitis B virus covalently closed circular DNA[J].Hepatobiliary Pancreat Dis Int, 2018, 19 (18) :261-269.
    [15]QU B, NI Y, LEMPP FA, et al.T5 exonuclease hydrolysis of hepatitis B virus replicative intermediates allows reliable quantification and fast drug efficacy testing of covalently closed circular DNA by PCR[J].J Virol, 2018, 92 (23) :e01117-e01118.
    [16]YEH CT, CHIU HT, CHU CM.G1 phase dependent nuclear localization of rcDNA and aphindicolin induced HBV cccDNA[J].J Med Virol, 1998, 55 (5) :42-50.
    [17]GUO YC, SHENG SC, NIE B, et al.Development of magnetic capture hybridization and quantitative polymerase chain reaction for hepatitis B virus covalently closed circular DNA[J].Hepat Mon, 2015, 15 (6) :729-736.
    [18]MARGERIDON S, CARROUE DS, CHEMIN I, et al.Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA[J].Antimicrob Agents Chemother, 2008, 52 (9) :3068-3073.
    [19]ZHONG YW, HAN JQ, ZOU ZS, et al.Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffinembedded liver tissue using rolling circle amplification in combination with real-time PCR[J].Clin Chim Acta, 2011, 412 (6) :1905-1911.
    [20]ZHONG YW, HU SY, XU C, et al.A novel method for detection of HBV cccDNA in hepatocytes using rolling circle amplification combined with in situ PCR[J].BMC infect Dis, 2014, 14:608-619.
    [21]ZHANG XN, LU W, ZHENG Y, et al.In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection[J].J Clin Investig, 2016, 126 (2) :1079-1092.
    [22]WHITE RA, QUAKE SR, CURR K.Digital PCR provides absolute quantitation of viral load for an occult RNA virus[J].J Virol Methods, 2011, 179 (6) :45-50.
    [23]HINDSON BJ, NESS KD, MASQUELIER DA, et al.Highthroughput droplet digital PCR system for absolute quantitation of DNA copy number[J].Anal Chem, 2011, 83 (12) :8604-8610.
    [24]VOGELSTEIN B, KINZLER KW.Digital PCR[J].Proc Natl Acad Sci U S A, 1999, 96 (4) :9236-9241.
    [25]HAYDEN RT, GU Z, INGERSOLL J.Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus[J].J Clin Microbiol, 2013, 51 (11) :540-546.
    [26]MU D, YAN L, TANG H, et al.A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system[J].Biotechnol Lett, 2015, 37 (10) :2063-2073.
    [27]CAVIGLIA GP, ABATE ML, TANDOI F, et al.Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR:A new tool to detect occult infection[J].J Hepatol, 2018, 69 (2) :301-307.
    [28]WALLRAPP A, RIESENFELD SJ, BURKETT PR, et al.The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation[J].Nature, 2017, 549 (7672) :351-356.
    [29]YILMAZ S, SINGH AK.Single cell genome sequencing[J].Curr Opin Biotechnol, 2012, 23 (3) :437-443.
    [30]ZONG CZ, LU SJ, CHAPMAN AR, et al.Genome-wide detection of single nucleotide and copy number variations of a single human Cell[J].Science, 2012, 338 (6114) :1622-1626.
    [31]LU SJ, ZONG CZ, XIE XS, et al.Probing meiotic recombination and aneuploidy of single sperm cells by whole genome sequencing using MALBAC[J].Science, 2012, 338 (6114) :1627-1630.
    [32]HUANG JT, YANG Y, LIU SM, et al.A highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum[J].J Mol, 2018, 20 (3) :334-343.
    [33]ZOULIM F.New insight on hepatitis B virus persistence from the study of intrahepatic viral HBV cccDNA[J].J Hepatol, 2005, 42 (3) :302-308.
    [34]LUCIFORA J, SALVETTI A, MARNIQUET X, et al.Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (HBV cccDNA) in mice transduced with a recombinant AAV-HBV vector[J].Antiviral Res, 2017, 145 (9) :14-19.
    [35]YUEN MF, WONG DK, SUM SS, et al.Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNAof chronic hepatitis B infection[J].Am J Gastroenterol, 2005, 100 (5) :1099-1103.
    [36]CHEN YJ, HE ML.HBV cccDNA in patients'sera as an indicator for HBV reactivation and an early signal of liver damage[J].World J Gastroenterol, 2004, 10 (1) :82-85.
  • Relative Articles

    [1]Jie LU, Dingchun LI, Ye LIU, Linna YUAN, Zhiwen DUAN, Wu LI. Clinical efficacy of low-dose plasma exchange combined with double plasma molecular absorption system/hemoperfusion in treatment of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2526-2531. doi: 10.3969/j.issn.1001-5256.2022.11.017
    [2]Wu YiChen, Yao HongYu, Wang KaiLi, Jiang QiYu, Liu Chang, Xing HanQian, Liu SuXia, You ShaoLi, Zhao Jun. Effect of plasma exchange on bioactivity of peripheral blood CD34+ cells in patients with acute-on-chronic (subacute) liver failure[J]. Journal of Clinical Hepatology, 2018, 34(11): 2383-2387. doi: 10.3969/j.issn.1001-5256.2018.11.023
    [3]Li Shuang, Chen Yu. Coping with shortage of plasma-The new therapeutic pattern of non-bioartificial liver[J]. Journal of Clinical Hepatology, 2017, 33(9): 1687-1692. doi: 10.3969/j.issn.1001-5256.2017.09.012
    [4]Hou HuanRong, Shang Jia, Kang Yi, Li YuKui, Ceng YanLi, Ding GangQiang, Mao ZhongShan, Xiao ErHui. Clinical effect of plasma exchange combined with hemofiltration in patients with subacute liver failure induced by antitubercular agents[J]. Journal of Clinical Hepatology, 2016, 32(2): 342-346. doi: 10.3969/j.issn.1001-5256.2016.02.030
    [5]Wang QingHai, Tian Yi. Clinical efficacy of modulation of intestinal microecology and plasmapheresis for preventing and treating multiple organ failure in patients with severe hepatitis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1426-1429. doi: 10.3969/j.issn.1001-5256.2015.09.015
    [6]Yu BingXue, Wu JianLin, Wu JiZhou, Wang ZunFu. Effect of non-bioartificial liver support system on serum manganese levels in patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2015, 31(8): 1311-1313. doi: 10.3969/j.issn.1001-5256.2015.08.031
    [7]Zhang LiangJie, Chen HuiJuan, Zhao ShouSong. Effects of artificial liver plasma exchange on cytokines in patients with liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 578-581. doi: 10.3969/j.issn.1001-5256.2015.04.024
    [8]Wang Xian, Wang ShaoYang, Huang DeDong, Chen Jian, Chen DeLiang. Analysis of short-term prognostic factors in patients with HBV-related acute-on-chronic liver failure treated with artificial liver support system[J]. Journal of Clinical Hepatology, 2014, 30(4): 367-369. doi: 10.3969/j.issn.1001-5256.2014.04.020
    [9]Wu ShaoHong, Gan JianHe, Huang XiaoPing, Lin Hua, Lu NianFang, Wu JiangQuan, Zheng RuiQiang. Clinical effect of albumin dialysis combined with plasma perfusion in treatment of liver failure[J]. Journal of Clinical Hepatology, 2014, 30(5): 434-437. doi: 10.3969/j.issn.1001-5256.2014.05.013
    [10]Zhang Lin, Zhao ShouSong. Clinical efficacy of plasma exchange therapy in treatment of liver failure[J]. Journal of Clinical Hepatology, 2014, 30(10): 1015-1019. doi: 10.3969/j.issn.1001-5256.2014.10.010
    [11]Hu QiJiang, Jiang YingAn. Evaluation of the therapeutic efficacy of lamivudine combined with plasma exchange for treating acute-on-chronic hepatitis B liver failure [J]. Journal of Clinical Hepatology, 2013, 29(2): 107-109.
    [12]Zhou Jian, Wan Hong. Relationship between changes in serum cytokine levels after artificial liver therapy and clinical prognosis in patients with liver failure[J]. Journal of Clinical Hepatology, 2013, 29(7): 535-537. doi: 1001-5256 (2013) 07-0535-03
    [13]Zhang AiMin, You ShaoLi, Wan ZhiHong, Rong YiHui, Zhu Bing, Zang Hong, Xin ShaoJie. Combination therapy of plasma perfusion, plasma exchange, and entecavir in patients with hepatitis B acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 744-747.
    [14]Liao JinMao, Li ZhuoRi, Hu XiaoXuan. The therapeutic effect of plasma exchange therapy in patients with severe hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(4): 302-304.
    [15]Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
    [18]Gao QingWei, Hu MeiTing, Yuan DeSheng, Wang Yong, Li BenKe, Han Guang, Wang RuGang, Sun WeiXiang. Analysis of influence factor and efficacy of plasma exchange therapy for chronic severe hepatitis B[J]. Journal of Clinical Hepatology, 2007, 23(5): 349-351.
  • Cited by

    Periodical cited type(30)

    1. 邹暾,龙文兴,周定中,周忠威,彭俊. 原发性肝癌采用肝动脉化疗栓塞术联合RFA的疗效及对血清miR-202、FHIT和P16蛋白水平的影响. 湘南学院学报(医学版). 2024(01): 27-29+78 .
    2. 余令兵. TACE中灌注吡柔比星治疗原发性肝癌的临床疗效及对免疫功能、血清肿瘤标志物水平的影响. 中国卫生工程学. 2024(02): 238-240+243 .
    3. 王娟,田宁,刘超,张山燕,周远. 肝动脉化疗栓塞联合靶向药物及免疫检查点抑制剂治疗中晚期肝癌的效果及对患者生存时间的影响. 大医生. 2024(07): 36-39 .
    4. 胡迎超. 血清甲胎蛋白和巨噬细胞移动抑制因子水平与原发性肝癌肝动脉化疗栓塞术患者预后的关系. 慢性病学杂志. 2023(01): 116-118 .
    5. 周菲菲,黄荣,蒋军,毛晓帆. 平均血小板体积/淋巴细胞比值对原发性肝癌SBRT治疗预后的评估价值. 西部医学. 2023(04): 563-567 .
    6. 何翠瑛,苏贞栋,陈燕红,周林荣,杨宇,姚清深. 阿帕替尼联合TACE治疗原发性肝癌复发生存的影响因素分析. 中西医结合肝病杂志. 2023(04): 298-302 .
    7. 张栋华,宋爱军,胡海军,刘朝阳. 经导管动脉化疗栓塞联合射频消融术治疗原发性肝癌患者的临床疗效. 癌症进展. 2023(08): 858-861 .
    8. 王如芹,高振东,高宗毅. 影响立体定向放射治疗原发性肝癌效果的相关因素分析. 中国基层医药. 2022(02): 285-290 .
    9. 刘爽. 基于聚焦解决模式的放松训练干预在肝癌射频消融术围术期护理中的应用效果评估. 黑龙江医学. 2022(01): 76-78 .
    10. 兰海涛,黄真婷,王小星. 超选择性肝动脉化疗栓塞术联合阿帕替尼对中晚期原发性肝癌患者血清MMP表达的影响. 数理医药学杂志. 2022(04): 597-599 .
    11. 张雪婷,周祖邦,薛亚娥,张明华,杜学晴. TACE联合热消融与单独TACE治疗结直肠癌肝转移疗效:Meta分析. 中国介入影像与治疗学. 2022(05): 278-283 .
    12. 杜炜玮,段铮,胡斌. 经皮RFA治疗原发性肝癌的效果及对血清TGF-β1、EGR2水平的影响. 分子诊断与治疗杂志. 2022(04): 635-638 .
    13. 武文华,冯秦辉,蔡芝芳,贾晓黎,杨锐华,党双锁. 经导管动脉化疗栓塞术联合超声引导射频消融术治疗原发性肝癌对疗效及免疫功能的影响. 中国医师进修杂志. 2022(05): 459-464 .
    14. 王瑛,袁鹤立,赵利,张亚丽,马向明. 伴营养不良风险的原发性肝癌患者临床特征及预后因素分析. 中西医结合肝病杂志. 2022(06): 494-498 .
    15. 柯映平,叶绍光,卢舜彬. 肝动脉化疗栓塞术联合FOLFOX方案持续性动脉灌注化疗在巴塞罗那B期原发性肝癌患者中的应用效果. 中国当代医药. 2022(18): 73-76 .
    16. 张贻庆,崔贵医,杨磊,刘刚,冯世杰,王劲. 肝肿瘤切除术与射频消融术治疗原发性肝癌的疗效及其对血清AFP、CEA、CA125水平的影响. 实用癌症杂志. 2022(08): 1316-1319 .
    17. 孙玉,张洪海,袁春旺,龙江,郑加生,张永宏. C反应蛋白/白蛋白比值影响肝动脉栓塞联合微波消融治疗中期肝细胞癌的预后. 肝胆胰外科杂志. 2022(10): 587-592 .
    18. 郝晓光,李伟靖,朱丽娜,史博,艾宁,吴勇超,李智岗. 中晚期肝癌患者经导管化疗栓塞治疗后序贯射频消融手术治疗时机的选择. 介入放射学杂志. 2022(09): 908-912 .
    19. 章甜,贾思静,孙冬雪,龙奉玺,唐东昕,杨柱. 拉米夫定联合TACE治疗HBV相关性中晚期肝癌的Meta分析. 临床医学研究与实践. 2021(13): 36-41+47 .
    20. 付卫东,尚靖智. 肝动脉化疗栓塞术联合经皮射频消融术治疗中晚期肝癌的临床疗效评价. 吉林医学. 2021(05): 1095-1098 .
    21. 谷涛,于经瀛. 肝动脉化疗栓塞术治疗原发性进展性肝细胞癌新进展. 协和医学杂志. 2021(03): 380-385 .
    22. 刘人杰. 索拉菲尼治疗原发性肝癌的效果及对患者血清HSP90α、VEGF水平的影响. 中国医学创新. 2021(14): 15-19 .
    23. 高磊磊,秦帅鑫,陈威,候振国. TACE联合RFA治疗中期原发性肝癌的疗效及对患者血清GP73、AFP和AFP-L3水平的影响. 临床和实验医学杂志. 2021(13): 1388-1391 .
    24. 金文彪. 肝动脉化疗栓塞联合射频消融在原发性肝癌中的价值. 中国卫生标准管理. 2021(17): 48-51 .
    25. 范隼,钟鹏,巫兆国. 经肝动脉化疗栓塞联合同步射频消融术治疗肝癌的初步临床研究. 吉林医学. 2021(10): 2389-2390 .
    26. 曹昆昆,李晓伟,付志刚,翟健,曲增强,丁宁. 微波消融同步联合经导管动脉化疗栓塞治疗膈下肝细胞癌. 中国介入影像与治疗学. 2021(11): 659-662 .
    27. 卢毅,周任. 肝动脉化疗栓塞联合射频消融治疗原发性小肝癌的临床效果及对患者免疫功能的影响. 广西医学. 2021(18): 2161-2165 .
    28. 何勇. 肝动脉介入化疗栓塞术联合阿帕替尼在晚期肝癌中的应用. 临床医药实践. 2020(03): 181-183 .
    29. 徐蓉,华忠. 肝硬化并发原发性肝癌的流行病学特征、危险因素及相关预防干预对策研究. 中西医结合肝病杂志. 2020(04): 357-359+366 .
    30. 刘峥嵘,俞巍. 肝动脉化疗栓塞术和肝动脉栓塞术治疗肝细胞癌的疗效. 血管与腔内血管外科杂志. 2019(02): 139-143 .

    Other cited types(2)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2904) PDF downloads(482) Cited by(32)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return